calling karmaswimswami, page-7

Thanks Dank,

I think the argument about AAV8 is somewhat moot now. We are going ahead with TT-034 using AAV8 so by June/July this year Benitec should have some idea about the efficiency of the vector when they compare the first cohort results with those of the mice and NHP models at similar doses.

Certainly by this time next year, Benitec will know if the vector has done its job. This will prove one way or another who is right in this debate. Dr Kay may then have to eat humble pie.

The only strange thing which I don't understand is why we did a deal with uniQure for the AAV5 vector for HBV. Surely, if TT-034 is successful, we would stick with AAV8 as the vector for HBV?